GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that Pfizer Inc. (NYSE: PFE) has dosed the first patient in the RESET (Rivipansel: Evaluating Safety, Efficacy and Time to Discharge) study - a Phase 3 clinical trial assessing the efficacy and safety of rivipansel for the treatment of vaso-occlusive crisis (VOC) in patients hospitalized with sickle cell disease who are six years of age or older. The start of this trial triggered the second of two milestone payments from Pfizer to GlycoMimetics totaling $35 million for Phase 3 initiation. GlycoMimetics received a $15 million milestone payment from Pfizer in May 2014.

The global population is aging as life expectancy increases. That means not only is demand for healthcare rising, but the very nature of that care is changing. In this interview, the CEO of Swiss pharmaceutical company Novartis, Joseph Jimenez, discusses with McKinsey’s Rik Kirkland issues including the emerging need for regenerative medicine, how digitization is driving innovation, and why Novartis is shifting to an outcomes-based approach for patient treatments. An extended and edited transcript of Jimenez’s remarks follows.

The Mayo Clinic’s Jacksonville, Florida unit and Silver Spring, Maryland-based biotechnology company United Therapeutics Corporation have announced that they will collaborate on construction and operation of a lung restoration center to be located on Mayo’s Jacksonville campus. The project’s goal is to significantly increase the volume of lungs available for transplants for a range of patients with various lung diseases, including those with PAH, by preserving and restoring selected marginal donor lungs, thereby making them viable for transplantation.

Confucius says “To Get Bigger Sometimes You Must Be Smaller.” Alright, so I made that up but that seems to be the thinking behind GlaxoSmithKlein’s (GSK - Analyst Report)  move to sell two meningitis vaccines to rival Pfizer (PFE - Analyst Report), in order to satisfy antitrust concerns after GSK’s recent acquisition of the vaccine business from Novartis. Sound confusing? Well it is.

In a cooperation between the Swiss Federal Institute of Technology in Zurich and Israel Institute of Technology (Technion) scientists have developed microscopic “nanoswimmers” that can penetrate  blood and even thicker liquids that exist within the body, something that corkscrews modeled on bacterial flagella have been disappointingly bad at. The tiny devices are made of three connected chains, one made of a polymer and two consisting of nanowires that can be influenced by an external magnetic field to flap in a given direction. This allows the system to control the direction in which the nanoswimmers are moving, so any on-board cargo such as drugs or some sort of nanoparticles can be precisely placed inside a tumor, for example.

Johns Hopkins is expanding its commitment to Baltimore on a number of fronts as the city faces "a time in need of new thinking and of urgent action," Johns Hopkins University President Ronald J. Daniels said Monday night at a gathering of community, political, and faith leaders in West Baltimore.

Daniels discussed efforts to support city schools, including new partnerships with Barclay Elementary/Middle School and Margaret Brent Elementary/Middle School, and the previously announced hiring of up to 300 Baltimore youth as part of the institution-wide summer jobs program. He pointed to Johns Hopkins' current ex-offender hiring program and work that is under way to develop more job training resources. He also previewed the roll-out of an expanded program to increase local hiring, purchasing, and contracting.

For those healthcare providers still resistant to technology, you've got a problem on your hands: You're going to be left behind. This is where healthcare it going – with or without you.

That's according to a new Accenture report, Healthcare Technology Vision 2015, which lays out five key trends in the industry that show adaptation might be the best business model.

Funding and Research Opportunities

The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:

Notices:

• Applicant Responsibilities in Maintaining the Integrity of NIH Peer Review
• (NOT-OD-15-106) National Institutes of Health
• Deadline for Final Reports Required for Grant Closeout
• (NOT-OD-15-111) National Institutes of Health
• Registration Open for the 2nd NIH Regional Seminar on Program Funding & Grants Administration - San Diego, CA - October 14-16, 2015
• (NOT-OD-15-113) National Institutes of Health

Program Announcements:

• Strategies to Increase Delivery of Guideline-Based Care to Populations with Health Disparities (R01)
• (PAR-15-279) 
• Application Receipt/Submission Date(s): October 21, 2015; June 21, 2016; October 21, 2016; June 21, 2017; October 20, 2017; and June 21, 2018, by 5:00 PM local time of applicant organization.
• Multidisciplinary Studies of HIV/AIDS and Aging (R01)
• (PAR-15-280) 
• Application Receipt/Submission Date(s): Multiple dates, see announcement.
• Multidisciplinary Studies of HIV/AIDS and Aging (R21)
• (PAR-15-282) 
• Application Receipt/Submission Date(s): Multiple dates, see announcement.

Please note that most links to RFAs, PAs, and Guide Notices will take you to the NIH Web site. RFPs will take you to FedBizOpps. Links to RFPs will not work past their proposal receipt date. Archived versions of RFPs posted on FedBizOpps can be found on the FedBizOpps site using the FedBizOpps search function. Under “Document to Search,” select Archived Documents.

Come to this information breakfast to learn about Relevant Health, the new accelerator now accepting applications from health tech startups for its Fall 2015 class!

Relevant Health's five-month program involves an intensive product-focused curriculum that gives founders of health tech startups the skills to define, develop, position and launch a viable health tech product. Companies admitted to the accelerator will have access to a cowork facility along with other support that includes up to $50,000 in funding, mentorship, development support from a pool of software engineers, and access to the local health tech ecosystem. The accelerator will be located in the Rockville Innovation Center.

The Institute of Human Virology (IHV) at the University of Maryland School of Medicine has received a five-year $24.5 million grant from the U.S. Centers for Disease Control and Prevention (CDC) through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) to partner with the Government of Botswana and impact the HIV/AIDS epidemic in Botswana, and to demonstrate that comprehensive HIV/AIDS treatment programs can stop the epidemic. PEPFAR is a $48 billion initiative launched in 2004 by former President George W. Bush, and continued by President Barack Obama, to combat major infectious diseases around the world, including HIV. The announcement was made on the heels of two recent IHV milestones including surpassing more than 1 million in patients in overseas care and treatment and a $50 million grant to combat HIV/AIDS in Zambia.

Victor and Lynne Brick, owners of Brick Bodies Fitness Services, Inc., a chain of coed and women-only health clubs, established the John W. Brick Mental Health Foundation (501c3) to support research and education in mental health. Honoring Victor’s brother John, who suffered from schizophrenia and eventually succumbed to complications from the disease, the John W. Brick Mental Health Foundation is dedicated to advancing research towards a comprehensive scientific understanding of relationships between exercise and mental health. The John W. Brick Mental Health Foundation will support a program of studies for that purpose, and the dissemination and application of results.

From SBIR Gateway:

There are a number of items I want to discuss with you but tonight there is only time for a few very time sensitive items that may be of interest to you.  Item #1 is the DoD SBIR submission site because Tuesday is your last full day to submit for the DoD 15.2 SBIR and 15.B STTR, (submission closes Wednesday June 24, at 6:00am edt).  Item # 2 is all important patent legislation which is supposed to be voted on this week in the House (H.R. 9 "Innovation Act") and the Senate's version (S. 1137 "Protecting American Talent and Entrepreneurship" [PATENT] Act).  Both of these items have the potential for causing small businesses plenty of grief. 

The Washington DC/Baltimore chapter of Women In Bio invites you to our July 8, 2015, networking happy hour, hosted by our newest sponsor BioHealth Innovation Inc. in Rockville, Maryland. We will be welcomed by Mr. Richard Bendis, Founder, President and CEO of BioHealth Innovation, Inc., followed by an evening of networking. Please come out and meet our new and exciting professionals from the DC/MD/VA area and learn more about the burgeoning biohealthcare industry in Maryland. Numbers are limited – register early!

Medical care today is episodic. We’re assessed by our doctors at our annual physical exams, and we’re treated by our doctors when symptoms of ill-health become manifest. In the periods in between, we’re unmoored and untended, perhaps engaging in behaviors that will sabotage our health. And because medical care today is driven by data derived from physician encounters, it becomes an explicitly physician-focused dynamic. If health care data were to be continually collected and assessed independent of physician encounters, medical care might finally be transformed to become a patient-focused dynamic instead, yielding efficiencies, improved outcomes, and lower costs.

MedCity ENGAGE is an executive-level event featuring the most innovative thinking from payers, providers, policymakers, health IT and beyond to highlight best-in-class approaches to one of the biggest challenges in healthcare: patient engagement. It will feature speakers discussing the current attempts to innovate in care delivery and reimbursement, along with the innovations that will form the backbone of technological infrastructure.

Thank you for joining us at Health Datapalooza 2015! The event was a huge success, bringing together more than 1,600 consumers, providers, payors, researchers, innovators, policy makers, and many more health data thought leaders for three days of networking and learning.

This year’s event highlights included a new series of main stage panel discussions as well as the announcement of the Obesity Challenge, a groundbreaking initiative to improve health and well-being in both the U.S. and U.K.

This is the first in a 3-part series about the use of crowdfunding in health and biotech start-ups. We start with the story of a tech start-up which set records for funding through a Kickstarter campaign, triggering interest in crowdfunding by entrepreneurs in capital-intensive industries.  Part 2 will discuss the JOBS Act and the government’s attempt to overcome regulatory hurdles facing companies which want to use crowdfunding to raise equity investment capital. Part 3 will address some Potential Dangers inherent in the system of crowdfunding being devised.  We hope you find the series educational and invite you to contact the authors with questions.

Same acronym… new innovative meaning. The Biotechnology Industry Organization… better known as BIO will soon become the Biotechnology Innovation Organization. This news release from BIO says the change is to highlight the scientific innovation the group brings.

“I’m pleased to announce that the BIO Board has approved a change to BIO’s name… from the Biotechnology Industry Organization to the Biotechnology Innovation Organization,” said BIO’s new Board Chair, Ron Cohen, CEO of Acorda Therapeutics. “Still BIO, but now with a name that better expresses the essence of what our member companies represent.”

Growing companies seeking to raise up to $50 million have a new financing option, starting Friday: a process that will open some private businesses to a wide pool of new investors.

More than three years in the making, the regulatory change, an expanded version of a rule known as Regulation A, is intended to let promising companies — the kinds typically backed by venture capitalists and wealthy angel investors — raise money by selling equity stakes to people of more modest means.

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today launched new Investigator® STR assay kits for analysis of DNA evidence in forensic laboratories in the United States. The new genetic fingerprint kits provide an integrated solution to simultaneously analyze multiple key genomic markers (short tandem repeats or STRs) for DNA matching. They incorporate the Investigator® Quality Sensor to evaluate the quality of DNA in each sample, a novel QIAGEN technology that enables labs to decide quickly which evidence may provide valuable results - solving cases while saving time and money.

The University of Maryland, Baltimore, will build a new interdisciplinary education facility thanks in part to a gift from a Baltimore construction company.

The university announced Wednesday that it’s getting $3 million from the Whiting-Turner Contracting Company. The money will go toward renovating a vacant building on the university campus in downtown Baltimore. When the work is finished, it will be home to the university’s Interprofessional Education Center.

One of the exciting and frustrating things about convergence, particularly in healthcare, is that it’s tough to predict how the hybrid technologies will find their way to market. The process of reaching that goal is filled with unexpected obstacles, twists and pivots.

United Therapeutics Corp., one of the region's largest bioscience firms, is planning a major expansion of its Silver Spring campus with plans to hire about 100 employees in the next three to six years.

The publicly traded firm, with about 200 D.C.-area employees and $340 million in net income in 2014, wants to develop a six-story building at the southwest corner of Spring Street and Colesville Road connecting to its existing corporate presence in the immediate area. The 121,724-square-foot building, to include new office, lab and retail space, would be developed on the site of what is now a Montgomery County-owned, three-story parking garage that is under contract for sale to United Therapeutics (NASDAQ: UTHR).

German pharma giant Bayer is uniting with researchers at Johns Hopkins University to ferret out new treatments for retinal diseases, signing a 5-year deal targeting early-stage R&D.

Under the agreement, Bayer will work alongside the school's Wilmer Eye Institute to spot new therapeutic targets, shed light on disease mechanisms and develop new drug delivery methods for back-of-the-eye ailments. Bayer will have exclusive rights to option any and all drug candidates that emerge from the collaboration, and the companies are keeping quiet on financial details.

Bayer HealthCare and Johns Hopkins University entered into a five-year collaboration to develop ophthalmic therapies that target retinal diseases. They will work together on discovery and development of drugs for treatment of eye diseases such as age-related macular degeneration and diabetic macular edema, among others.

72% percent of health IT leaders think consumer and patient considerations are the most important business issue affecting care delivery.

Registrants can now save $300 on MedCity ENGAGE on July 14-15 in Bethesda, MD. Sign up now to take advantage of advanced general registration.

MedCity ENGAGE is an executive-level event featuring the most innovative thinking from payers, providers, policymakers, health IT and beyond to highlight best-in-class approaches to one of the biggest challenges in healthcare: patient engagement. It will feature speakers discussing the current attempts to innovate in care delivery and reimbursement, along with the innovations that will form the backbone of technological infrastructure.

BioBuzz is an ongoing monthly networking group of professionals from all sectors of the Biotech/Pharma/Life-sciences industries. Each month we host a FREE event for like-minded people to come together and network, reconnect with past coworkers, build stronger relationships and share stimulating conversations in a welcoming atmosphere.

This month's event is made possible by our sponsor, Breezio (@brzio), who is helping to advance the pace of research and discovery through their Research Collaboration Platform. Join us at the upcoming Bethesda event - June 25th at Barking Dog Bar - to meet them and learn about Team Science.

Lake Whillans, in an effort to help level the playing field for entrepreneurs in the new world of healthcare investing, has partnered with MedCity News to deliver independent research on corporate venture capital in the life sciences. MedCityNews.com reached out to its 400,000 monthly readers, and more than 450 healthcare innovators familiar with corporate firms shared their insights.

Pharmaceuticals giant GlaxoSmithKline could reportedly become the latest takeover target in the industry.

According to the Daily Mail, market participants are speculating that the company may face an approach from Switzerland’s Roche or US company Johnson & Johnson at about 1900p per share.

Scientific American has released its list of the 100 most influential people in biotechnology.

I am honored to be included in this exclusive list and recognized for my thought leadership on the business of biotechnology.

There is always talk, sometimes tongue-in-cheek but mostly sort of serious, that a lot of jobs will be replaced by robots or computers. Maybe that new iPhone I just bought will replace me by year end. Venture capitalist Vinod Khosla thinks that the most doctors’ current functions will be replaced by algorithms; many believe that lots of white collar jobs, such as lawyers, accountants, and bankers will be replaced by machines with warmer personalities. Venture capitalists have already been “supplemented” with algorithms and, no doubt, there are plenty of people who would like to see us replaced by nearly anything metal—spatula, can opener–if they had their way. In Iron Man we see a world of robot-based soldiers going to war and in real life the echo of that is not so far off.

Only a year after its founding, Bethesda-based health tech company Aledade Inc. raised $30 million in a Series B fundraising, it announced Monday.

ARCH Venture Partners led the funding round with an investment from Series A investor Venrock, which first invested $4.5 million in Aledade to start the company last June.

Two years ago, a television cartoon in Pakistan made waves for its star, a superheroine named “Burka Avenger,” who promotes positive social change while clad in the titular billowing black silk outfit. With the tagline “don’t mess with the lady in black,” the show presents plotlines promoting gender equality, environmentalism and health.

H.R. 6, the 21st Century Cures Act, includes vital resources for the National Institutes of Health and important policy - See more at: http://energycommerce.house.gov/press-release/21st-century-cures-renews-commitment-biomedical-research-america#sthash.2aIzVevb.dpuf changes that will allow America’s most promising scientists and researchers to unleash the next generation of cures and therapies. As Greg Satell writes in Forbes, “science is what made America a technological superpower” and the 21st Century Cures Act would help to “renew our commitment to science and competitiveness.” The Alliance for Aging Research adds, “the pace of scientific discovery since the turn of the century has accelerated at a speed that was not possible a generation ago. [H.R. 6] was developed after the realization by leaders in Congress that the current health care innovation infrastructure needed improvement to accommodate those advances in science.”

Entrepreneurs beat long odds when they launch a company, scale it up and sell it to investors. Smith School alumnus Jason Cohen has done it five times in 15 years with brands such as Sensible Portions low-calorie snacks, Rickland Orchards yogurt, SkinnyPop popcorn and Mrs. Thinsters cookies. Now Cohen and his partners are focusing on identifying high-potential startups that need capital and expertise to grow. Their latest project is a jerky company called Chef’s Cut. “If we invest in your business, then we believe it can be a $50 million to $100 million business,” says Cohen, who lives in New Jersey. “And you’ll get a roadmap from an entrepreneur who has been in your shoes.” Part of that roadmap includes the following seven secrets of Cohen’s success.